{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T01:37:35Z","timestamp":1710985055890},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.remnie.2023.12.005","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T18:49:53Z","timestamp":1704394193000},"page":"84-90","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of the clinical radiopharmacist in patient safety during myocardial perfusion imaging with vasodilator stress agents"],"prefix":"10.1016","volume":"43","author":[{"given":"C.","family":"Salgado-Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Moreno-Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Guardia-Jimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sanchez-de-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Rebollo-Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ramirez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Santos-Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jimenez-Heffernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2023.12.005_bib0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12350-009-9062-4","article-title":"ASNC imaging guidelines for nuclear cardiology procedures","volume":"16","author":"Henzlova","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remnie.2023.12.005_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","article-title":"ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers","volume":"23","author":"Henzlova","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remnie.2023.12.005_bib0015","series-title":"Rapiscan (regadenoson). Summary of product characteristics","year":"2019"},{"key":"10.1016\/j.remnie.2023.12.005_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00259-013-2493-9","article-title":"Comparative study of the safety of regadenoson between patients with mild\/moderate chronic obstructive pulmonary disease and asthma","volume":"41","author":"Salgado-Garcia","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2023.12.005_bib0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","article-title":"A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease","volume":"19","author":"Prenner","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remnie.2023.12.005_bib0030","first-page":"283","article-title":"Safety of regadenoson in patients with severe chronic obstructive pulmonary disease","volume":"35","author":"Salgado-Garcia","year":"2016","journal-title":"Rev Esp Med Nucl Imagin Mol"},{"key":"10.1016\/j.remnie.2023.12.005_bib0035","first-page":"e12940","article-title":"Regadenoson stress testing: a comprehensive review with a focused update","volume":"13","author":"Elkholy","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.remnie.2023.12.005_bib0040","first-page":"e17929","article-title":"Role of clinical pharmacists in intensive care units","volume":"13","author":"Arredondo","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.remnie.2023.12.005_bib0045","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/CCM.0000000000004438","article-title":"Position paper on critical care pharmacy services (Executive summary): 2020 update","volume":"48","author":"Lat","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.remnie.2023.12.005_bib0050","first-page":"571","article-title":"Clinical pharmacists: practitioners who are essential members of your clinical care team","volume":"27","author":"Jacobi","year":"2016","journal-title":"Med Clin Condes"},{"key":"10.1016\/j.remnie.2023.12.005_bib0055","unstructured":"Estrategia para la Seguridad del Paciente de Andaluc\u00eda. Available from: https:\/\/www.picuida.es\/estrategia-para-la-seguridad-del-paciente-de-andalucia-nueva-version-2019\/. [Accessed 9 February 2022]."},{"key":"10.1016\/j.remnie.2023.12.005_bib0060","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s12350-022-03162-7","article-title":"Quality metrics for single-photon emission computed tomography myocardial perfusion imaging: an ASNC information statement","volume":"30","author":"Hage","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remnie.2023.12.005_bib0065","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00259-015-3139-x","article-title":"EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT\/CT","volume":"42","author":"Verbene","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2023.12.005_bib0070","series-title":"The radiopharmacist as a professional speciality: past, present and future (IAEA-TECDOC-1029)","author":"Wolf","year":"1998"},{"key":"10.1016\/j.remnie.2023.12.005_bib0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0001-2998(96)80028-6","article-title":"Clinical radiopharmacy: principles and practices","volume":"26","author":"Rhodes","year":"1996","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.remnie.2023.12.005_bib0080","series-title":"Nuclear pharmacy. Concepts and applications","first-page":"205","article-title":"Interventional agents used in nuclear medicine","author":"Galbraith","year":"2010"},{"key":"10.1016\/j.remnie.2023.12.005_bib0085","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2015.09.025","article-title":"The role of the clinical pharmacist in the care of patients with cardiovascular disease","volume":"66","author":"Dunn","year":"2015","journal-title":"JACC"},{"key":"10.1016\/j.remnie.2023.12.005_bib0090","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/1078155220943964","article-title":"Clinical pharmacy in onco-hematology and bone marrow transplant: a valuable contribution to improving patient safety","volume":"27","author":"Visacri","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.remnie.2023.12.005_bib0095","first-page":"1","article-title":"Pharmacists\u2019 interventions on 2 years of drug monitoring in an oncology pediatric inpatient ward","author":"Agnol","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.remnie.2023.12.005_bib0100","unstructured":"Arizona Science Foundation. CredibleMeds\u00ae. https:\/\/crediblemeds.org\/index.php?rf=US. [Accessed 20 September 2022]."},{"key":"10.1016\/j.remnie.2023.12.005_bib0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can Pharm J"},{"key":"10.1016\/j.remnie.2023.12.005_bib0110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.remnie.2023.12.005_bib0115","first-page":"1866","article-title":"Identification of risk of QT prolongation by pharmacist when conducting medications reviews in residential aged care settings: a missed opportunity?","volume":"8","author":"Christensen","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2023.12.005_bib0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.nrl.2012.07.011","article-title":"Ultrasound measurement of carotid stenosis: recommendations from the Spanish Society of Neurosonology","volume":"28","author":"Serena","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.remnie.2023.12.005_bib0125","article-title":"Seizure: an adverse effect of regadenoson in myocardial perfusion imaging","volume":"2019","author":"Radwan","year":"2019","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.remnie.2023.12.005_bib0130","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/ijms15022024","article-title":"Adenosine receptors: expression, function and regulation","volume":"15","author":"Sheth","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.remnie.2023.12.005_bib0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12350-011-9461-1","article-title":"Seizures associated with regadenoson: a case series","volume":"18","author":"Page","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remnie.2023.12.005_bib0140","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/FAD.0000000000000016","article-title":"Drugs that lower the seizure threshold","volume":"298","author":"Hitchings","year":"2016","journal-title":"Adverse Drug React Bull"},{"key":"10.1016\/j.remnie.2023.12.005_bib0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1073858404269112","article-title":"Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies","volume":"11","author":"Boison","year":"2005","journal-title":"Neuroscientist"},{"key":"10.1016\/j.remnie.2023.12.005_bib0150","series-title":"General electric healthcare","author":"Myoview [package insert]","year":"2021"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808923001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808923001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:02:56Z","timestamp":1710979376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808923001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2253808923001003"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2023.12.005","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the clinical radiopharmacist in patient safety during myocardial perfusion imaging with vasodilator stress agents","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2023.11.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}